HRSA Denounces J&J’s Proposed Rebate Model
Today, the Health Resources and Services Administration (HRSA) issued a letter to Johnson and Johnson Health Care System Inc. (J&J) calling for the manufacturer to “cease implementation of its rebate…
Fighting to Preserve the Benefits of the 340B Program
Today, the Health Resources and Services Administration (HRSA) issued a letter to Johnson and Johnson Health Care System Inc. (J&J) calling for the manufacturer to “cease implementation of its rebate…
Beginning October 1, 2024, AstraZeneca will require all covered entities to submit 340B claims utilization data to ESP™ as a pre-requisite for designating a single contract pharmacy. This announcement, released…
EMD Serono (EMDS) announced that it will apply its contract pharmacy restrictions to all covered entities beginning October 1, 2024. EMDS is allowing an exception to Ryan White Clinics for purchases…
Johnson & Johnson Health Care System Inc. (J&J) announced last week that, effective October 15, 2024, disproportionate share hospital (DSH) covered entities will no longer have access to up-front 340B…
CMS announced that it expects to release a final National Coverage Determination (NCD) late next month that will move the PrEP coverage benefit from Medicare Part D to Medicare Part…
On June 21, 2024, the American Journal of Managed Care ran an article titled “Protecting the 340B Program Vital for Providing the Best Care to Patients With HIV” that detailed…
On June 11, 2024, the Times West Virginian ran a story titled “Federal drug pricing program 340B important for rural health care providers in W.Va.” which articulates and underscores the…
RWC-340B Fact Sheet – Oppose 340B ACCESS Act
RWC-340B was asked to sign onto the attached letter to CMS commenting on its May 3, 2024 Draft Guidance implementing aspects of the Inflation Reduction Act (IRA). 340B Health drafted the…
RWC-340B Comparison of 340B Principles and Legislation Chart. Comparison of 340B Principles and Legislation Chart.pdf